Current State of Immunosuppression: Past, Present, and Future

Area of Science:

• Transplantation immunology
• Immunosuppression strategies

Background:

• Solid-organ transplantation success hinges on understanding alloimmune-mediated graft destruction.
• Current immunosuppressive protocols combine calcineurin inhibitors and antiproliferative agents, significantly reducing acute rejection rates.

Purpose of the Study:

• To review current immunosuppression protocols in solid-organ transplantation.
• To discuss the limitations of existing therapies in improving long-term graft and patient survival.
• To explore emerging strategies for inducing tolerance and minimizing adverse events.

Main Methods:

• Review of current immunosuppressive drug combinations (e.g., calcineurin inhibitors, antiproliferatives, mTOR inhibitors).
• Analysis of the role of induction therapy in various solid-organ transplants.
• Examination of novel approaches like belatacept and mesenchymal stem cells for tolerance induction.

Main Results:

• Combination immunosuppressive therapy has markedly decreased acute rejection incidence and intensity.
• One-year graft and patient survival rates are high (98% for kidney, >80% for heart/lung transplants).
• Long-term graft and patient survival have not improved over the past two decades.

Conclusions:

• While current immunosuppression effectively prevents acute rejection, it has not translated to improved long-term outcomes.
• New strategies, including costimulatory inhibitors and cell-based therapies, are being investigated to induce tolerance and mitigate long-term adverse effects.
• Minimizing maintenance immunosuppression and preventing associated toxicities are key future goals in transplantation.